# US 2026/0027375 A1 · Systems and methods for electroconvulsive therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0027375 A1
- Document ID: US20260027375A1
- Status: Published application
- Kind: A1
- Application number: 19/145,154
- Filed: 2024-01-04
- Published: 2026-01-29
- Earliest claimed: 2023-01-04
- Inventors: Christopher Abbott; Zhi-De Deng; Joel Upston; Thomas Jones; Abhisheck Datta
- Web page: https://patentgrep.com/patent/US20260027375A1

## CPC

- A61N 1/36025: {for treating a mental or cerebral condition}
- A61N 1/38: for producing shock effects
- A61B 5/4094: {Diagnosing or monitoring seizure diseases, e.g. epilepsy}
- A61N 1/3603: {Control systems}
- A61N 1/36031: {using physiological parameters for adjustment}
- A61N 1/36034: {specified by the stimulation parameters}
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

The present disclosure relates to methods of electroconvulsive therapy (ECT) for a patient's brain based on determining an optimal individualized current amplitude for a patient by (1) dividing an optimal E-field strength (optimal Ebrain) by a baseline E-field strength (baseline Ebrain) of the patient's brain, or (2) performing an initial treatment to determine a patient's amplitude titrated seizure threshold (STa), followed by use of a multiplier value multiplied by the STa for an individualized amplitude for subsequent treatments. Methods of ECT using optimal individualized current amplitude provide an antidepressant effect and reduce adverse cognitive effects on the patient's brain.

## Claims

### Claim at position 1

1-43. (canceled)

### Claim 44

A method of electroconvulsive therapy (ECT) for a patient's brain to treat a neuropsychiatric disorder, comprising:
determining an individualized amplitude for the patient by performing an amplitude-determined seizure-titration procedure on the patient's brain, wherein the amplitude-determined seizure-titration procedure comprises stimulating the patient's brain with increasing amplitudes until seizure activity is initiated, and wherein the amplitude at which seizure activity is initiated is the seizure-determined amplitude or STa for the patient;
multiplying the patient's STa by a multiplier value to determine the patient's individualized amplitude; and
applying the individualized amplitude to the patient's brain with a fixed placement of extracranial electrodes to improve the neuropsychiatric disorder.

### Claim 45 (depends on 44)

The method of claim 44, wherein the amplitude-determined seizure-titration procedure occurs at a first treatment session with the patient, and wherein applying the individualized amplitude to the patient's brain occurs at one or more subsequent treatments.

### Claim 46 (depends on 45)

The method of claim 45, wherein the number of subsequent treatments is based on improving a neuropsychiatric disorder without cognitive impairment of the patient, wherein the cognitive impairment comprises one or more of amnesia, executive dysfunction, or verbal dysfluency.

### Claim 47 (depends on 44)

The method of claim 44, wherein the multiplier value is approximately 2 to approximately 3.

### Claim 48 (depends on 44)

The method of claim 44, wherein the individualized amplitude is applied to the patient's brain with right unilateral electrode placement, a pulse width of approximately 0.3 to approximately 1.0 ms, a frequency of approximately 20 to approximately 120 hertz, and a pulse train duration of approximately 8 seconds.

### Claim 49 (depends on 44)

The method of claim 44, wherein stimulating the patient's brain comprises placement of extracranial electrodes on the patient's head and applying an amplitude starting at approximately 100 mA with incremental increases in amplitude until seizure activity occurs.

### Claim 50 (depends on 44)

The method of claim 44, wherein the initiation of seizure activity is determined by right lower extremity motor activity, EEG activity for 20 seconds, or both.

### Claim 51 (depends on 44)

The method of claim 44, wherein the neuropsychiatric disorder is any one or more of major depressive disorder (MDD), schizophrenia, schizoaffective disorder, or bipolar disorder.

### Claim 52 (depends on 44)

The method of claim 44, wherein the amplitude-determined seizure-titration procedure comprises stimulating the patient's brain with increasing amplitudes with a fixed frequency and pulse train duration until seizure activity is initiated.

### Claim 53 (depends on 52)

The method of claim 52, wherein the frequency is approximately 20 to approximately 120 hertz and the pulse train duration is approximately 8 seconds, and wherein a range of amplitudes at which seizure activity occurs is from approximately 100 mA to approximately 700 mA.

### Claim 54

A method of electroconvulsive therapy (ECT) for a patient's brain, comprising:
determining an optimal individualized current amplitude for the patient by dividing an optimal E-field strength (optimal Ebrain) by a baseline E-field strength (baseline Ebrain) of the patient's brain, wherein the optimal Ebrain is an E-field strength sufficient to induce an antidepressant effect without cognitive impairment, and wherein the baseline Ebrain is determined by finite element modeling using structural MRI of the patient's brain with a fixed placement of extracranial electrodes and comprises at least a 90th percentile of E-field magnitudes from all voxels in the patient's brain; and
applying the optimal individualized current amplitude to the patient's brain with the fixed placement of the extracranial electrodes, wherein the optimal individualized current amplitude induces a seizure activity that has an antidepressant effect.

### Claim 55 (depends on 54)

The method of claim 54, wherein the optimal Ebrain is approximately 110 Volts/meter to approximately 120 Volts/meter.

### Claim 56 (depends on 54)

The method of claim 54, wherein Ebrain is based on an E-field of the patient's whole brain.

### Claim 57 (depends on 54)

The method of claim 54, wherein the finite element modeling comprises segmentation of the brain, extracranial electrode placement on the patient's scalp, tessellation of volume into a mesh, and determining the patient's baseline Ebrain.

### Claim 58 (depends on 54)

The method of claim 54, wherein the 90th percentile of E-field magnitudes ranges from approximately 0.1 to approximately 0.2 Volts/meter per milliampere of current.

### Claim 59 (depends on 54)

The method of claim 54, wherein the method induces the antidepressant effect without cognitive impairment of the patient, wherein the cognitive impairment comprises one or more of amnesia, executive dysfunction, or verbal dysfluency.

### Claim 60 (depends on 54)

The method of claim 54, wherein the optimal individualized current amplitude is applied to the patient's brain at a pulse width of approximately 0.3 to approximately 1.0 milliseconds.

### Claim 61 (depends on 54)

The method of claim 54, wherein the optimal individualized current amplitude is applied to the patient's brain for a pulse train duration of approximately 0.5 to approximately 8 seconds.

### Claim 62 (depends on 54)

The method of claim 54, wherein the optimal individualized current amplitude ranges from approximately 600 mA to approximately 1200 mA.

### Claim 63

A method of determining an optimal individualized current amplitude for a patient for use in electroconvulsive therapy (ECT) to the patient's brain, comprising:
determining a baseline E-field strength (baseline Ebrain) of the patient's brain by finite element modeling using structural MRI of the patient's brain with a fixed placement of extracranial electrodes, wherein the baseline Ebrain comprises at least a 90th percentile of E-field magnitudes from all voxels in the patient's brain; and
dividing an optimal E-field strength (optimal Ebrain) by the patient's baseline Ebrain to produce the optimal individualized current amplitude for the patient, wherein the optimal Ebrain is an E-field strength sufficient to induce an antidepressant effect without cognitive impairment.
